Association of Complete Blood Cell Count-Derived Inflammatory Biomarkers with Psoriasis and Mortality

References

• Hoffmann JHO, Enk AH. Evaluation of Psoriasis Area and Severity Index Thresholds as Proxies for Systemic Inflammation on an Individual Patient Level. Dermatology. 2022;238(4):609–614.
   PubMed Web of Science ®Google Scholar
• Kanda N, Hoashi T, Saeki H. Nutrition and Psoriasis. Int J Mol Sci. 2020;21(15):5405.
   PubMed Web of Science ®Google Scholar
• Kanda N, Hoashi T, Saeki H. The Defect in Regulatory T Cells in Psoriasis and Therapeutic Approaches. J Clin Med. 2021;10(17):3880.
   PubMed Web of Science ®Google Scholar
• Lopez-Candales A, Hernandez Burgos PM, Hernandez-Suarez DF, Harris D. Linking Chronic Inflammation with Cardiovascular Disease: from Normal Aging to the Metabolic Syndrome. J Nat Sci. 2017;3(4):56.
   Google Scholar
• Nguyen HT, Vo LDH, Pham NN. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as inflammatory markers in psoriasis: a case-control study. Dermatol Reports. 2023;15(1):9516.
   PubMed Web of Science ®Google Scholar
• von Stebut E, Reich K, Thaci D, et al. Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks. J Invest Dermatol. 2019;139(5):1054–1062.
   PubMed Web of Science ®Google Scholar
• Lynch M, Ahern T, Sweeney CM, et al. Adipokines, psoriasis, systemic inflammation, and endothelial dysfunction. Int J Dermatol. 2017;56(11):1103–1118.
   PubMed Web of Science ®Google Scholar
• Wei JC, Kim TH, Kishimoto M, et al. Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, Phase 3 trial. Ann Rheum Dis. 2021;80(8):1014–1021.
   PubMed Web of Science ®Google Scholar
• Seo SJ, Shin BS, Lee JH, Jeong H. Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: a randomized, Phase III, double-blind, placebo-controlled study. J Dermatol. 2021;48(6):807–817.
   PubMed Web of Science ®Google Scholar
• Korkmaz M, Erylmaz MK. Systemic Inflammatory Markers Predicting the Overall Survival of Patients Using Tyrosine Kinase Inhibitors in the First-line Treatment of Metastatic Renal Cell Carcinoma. J Coll Physicians Surg Pak. 2023;33(6):653–658.
   PubMed Web of Science ®Google Scholar
• Hammad M, Shehata OZ, Abdel-Latif SM, El-Din AMM. Neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in Behcet’s disease: which and when to use? Clin Rheumatol. 2018;37(10):2811–2817.
   PubMed Web of Science ®Google Scholar
• Kosekli MA. Mean platelet volume and platelet to lymphocyte count ratio are associated with hepatitis B-related liver fibrosis. Eur J Gastroenterol Hepatol. 2022;34(3):324–327.
   PubMed Web of Science ®Google Scholar
• Seaoud E, Mohamed A, Elkot MA. The Role of the Platelet/Lymphocyte Ratio and Neutrophil/Lymphocyte Ratio in Predicting High-Risk Heart Score in Patients Admitted with Non-ST Elevation Acute Coronary Syndrome. Pulse. 2020;8(1–2):66–74.
   PubMed Web of Science ®Google Scholar
• Hirahara T, Arigami T, Yanagita S, et al. Combined neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts chemotherapy response and prognosis in patients with advanced gastric cancer. BMC Cancer. 2019;19(1):672.
   PubMedGoogle Scholar
• Urbanowicz T, Michalak M, Olasinska-Wisniewska A, et al. Neutrophil Counts, Neutrophil-to-Lymphocyte Ratio, and Systemic Inflammatory Response Index (SIRI) Predict Mortality after Off-Pump Coronary Artery Bypass Surgery. Cells. 2022;11(7):1124.
   PubMed Web of Science ®Google Scholar
• Hayran Y, Oktem A, Sahin B, Incel Uysal P, Alli N, Yalcin B. Elevated neutrophil to lymphocyte ratio as an indicator of secondary erythema nodosum, a retrospective observational study. Turk J Med Sci. 2019;49(2):624–634.
   PubMed Web of Science ®Google Scholar
• Korkmaz C, Demircioglu S. The Association of Neutrophil/Lymphocyte and Platelet/Lymphocyte Ratios and Hematological Parameters with Diagnosis, Stages, Extrapulmonary Involvement, Pulmonary Hypertension, Response to Treatment, and Prognosis in Patients with Sarcoidosis. Can Respir J. 2020;2020:1696450.
   PubMed Web of Science ®Google Scholar
• Tarkowski B, Lawniczak J, Tomaszewska K, Kurowski M, Zalewska-Janowska A. Chronic Urticaria Treatment with Omalizumab-Verification of NLR, PLR, SIRI and SII as Biomarkers and Predictors of Treatment Efficacy. J Clin Med. 2023;12(7):2639.
   PubMed Web of Science ®Google Scholar
• Asahina A, Kubo N, Umezawa Y, Honda H, Yanaba K, Nakagawa H. Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and mean platelet volume in Japanese patients with psoriasis and psoriatic arthritis: response to therapy with biologics. J Dermatol. 2017;44(10):1112–1121.
   PubMed Web of Science ®Google Scholar
• Strober B, Ryan C, van de Kerkhof P, et al. Recategorization of psoriasis severity: delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2020;82(1):117–122.
   PubMed Web of Science ®Google Scholar
• Shoji F, Kozuma Y, Toyokawa G, Yamazaki K, Takeo S. Complete Blood Cell Count-Derived Inflammatory Biomarkers in Early-Stage Non-Small-Cell Lung Cancer. Ann Thorac Cardiovasc Surg. 2020;26(5):248–255.
   PubMed Web of Science ®Google Scholar
• Zhou D, Yang H, Zeng L, et al. Calculated inflammatory markers derived from complete blood count results, along with routine laboratory and clinical data, predict treatment failure of acute peritonitis in chronic peritoneal dialysis patients. Ren Fail. 2023;45(1):2179856.
   PubMed Web of Science ®Google Scholar
• Qiu Z, Chen X, Geng T, et al. Associations of Serum Carotenoids With Risk of Cardiovascular Mortality Among Individuals With Type 2 Diabetes: results From NHANES. Diabetes Care. 2022;45(6):1453–1461.
   PubMed Web of Science ®Google Scholar
• Beddhu S, Baird BC, Zitterkoph J, Neilson J, Greene T. Physical activity and mortality in chronic kidney disease (NHANES III). Clin J Am Soc Nephrol. 2009;4(12):1901–1906.
   PubMed Web of Science ®Google Scholar
• Services USDoHaH. Poverty Guidelines, Research, and Measurement. Available from: http://aspe.hhs.gov/POVERTY/index.shtml. Accessed November 10, 2023.
   Google Scholar
• Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–1645.
   PubMed Web of Science ®Google Scholar
• Harden JL, Krueger JG, Bowcock AM. The immunogenetics of Psoriasis: a comprehensive review. J Autoimmun. 2015;64:66–73.
   PubMed Web of Science ®Google Scholar
• Kocaaga A, Kocaaga M. Psoriasis: an Immunogenetic Perspective. Glob Med Genet. 2022;9(2):82–89.
   PubMedGoogle Scholar
• Wu J, Yan L, Chai K. Systemic immune-inflammation index is associated with disease activity in patients with ankylosing spondylitis. J Clin Lab Anal. 2021;35(9):2639.
   Web of Science ®Google Scholar
• Ritchlin CT, Colbert RA, Gladman DD. Psoriatic Arthritis. N Engl J Med. 2017;376(21):2095–2096.
   PubMedGoogle Scholar
• Kim DS, Shin D, Lee MS, et al. Assessments of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in Korean patients with psoriasis vulgaris and psoriatic arthritis. J Dermatol. 2016;43(3):305–310.
   PubMed Web of Science ®Google Scholar
• Wang WM, Wu C, Gao YM, Li F, Yu XL, Jin HZ. Neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, and other hematological parameters in psoriasis patients. BMC Immunol. 2021;22(1):64.
   PubMed Web of Science ®Google Scholar
• Aktas Karabay E, Aksu Cerman A, Demir D, Kivanc Altunay I. The Effects of Systemic Psoriasis Therapies on the C-Reactive Protein and the Neutrophil-Lymphocyte Ratio. Ann Dermatol. 2019;31(6):601–610.
   PubMed Web of Science ®Google Scholar
• Annen S, Horiguchi G, Teramukai S, et al. Association of Transition of Laboratory Markers with Transition of Disease Activity in Psoriasis Patients Treated with Biologics. J Nippon Med Sch. 2022;89(6):587–593.
   PubMed Web of Science ®Google Scholar
• Zhou ZQ, Pang S, Yu XC, et al. Predictive Values of Postoperative and Dynamic Changes of Inflammation Indexes in Survival of Patients with Resected Colorectal Cancer. Curr Med Sci. 2018;38(5):798–808.
   PubMed Web of Science ®Google Scholar
• Xiao Z, Wang X, Chen X, et al. Prognostic role of preoperative inflammatory markers in postoperative patients with colorectal cancer. Front Oncol. 2023;13:1064343.
   PubMed Web of Science ®Google Scholar
• Fan Z, Ji H, Li Y, Jian X, Li L, Liu T. Relationship between monocyte-to-lymphocyte ratio and coronary plaque vulnerability in patients with stable angina. Biomark Med. 2017;11(11):979–990.
   PubMed Web of Science ®Google Scholar
• Ates AH, Aytemir K, Kocyigit D, et al. Association of Neutrophil-to-Lymphocyte Ratio with the Severity and Morphology of Coronary Atherosclerotic Plaques Detected by Multidetector Computerized Tomography. Acta Cardiol Sin. 2016;32(6):676–683.
   PubMed Web of Science ®Google Scholar
• Balta S, Ozturk C. The platelet-lymphocyte ratio: a simple, inexpensive and rapid prognostic marker for cardiovascular events. Platelets. 2015;26(7):680–681.
   PubMed Web of Science ®Google Scholar
• Dziedzic EA, Gasior JS, Tuzimek A, et al. Investigation of the Associations of Novel Inflammatory Biomarkers-Systemic Inflammatory Index (SII) and Systemic Inflammatory Response Index (SIRI)-With the Severity of Coronary Artery Disease and Acute Coronary Syndrome Occurrence. Int J Mol Sci. 2022;23(17):9553.
   PubMed Web of Science ®Google Scholar
• Terui H, Asano Y. Biologics for Reducing Cardiovascular Risk in Psoriasis Patients. J Clin Med. 2023;12(3):1162.
   PubMed Web of Science ®Google Scholar
• Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol. 2010;163(3):586–592.
   PubMed Web of Science ®Google Scholar
• Boehncke WH, Boehncke S, Tobin AM, Kirby B. The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011;20(4):303–307.
   PubMed Web of Science ®Google Scholar
• Boehncke WH. Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: causes and Consequences. Front Immunol. 2018;9:579.
   PubMed Web of Science ®Google Scholar
• Boehncke WH, Schon MP. Psoriasis. Lancet. 2015;386(9997):983–994.
   PubMed Web of Science ®Google Scholar
• Fiore M, Leone S, Maraolo AE, Berti E, Damiani G. Liver Illness and Psoriatic Patients. Biomed Res Int. 2018;2018:3140983.
   PubMed Web of Science ®Google Scholar
• Santus P, Rizzi M, Radovanovic D, et al. Psoriasis and Respiratory Comorbidities: the Added Value of Fraction of Exhaled Nitric Oxide as a New Method to Detect, Evaluate, and Monitor Psoriatic Systemic Involvement and Therapeutic Efficacy. Biomed Res Int. 2018;2018:3140682.
   PubMed Web of Science ®Google Scholar
• Kvist-Hansen A, Kaiser H, Wang X, et al. Neutrophil Pathways of Inflammation Characterize the Blood Transcriptomic Signature of Patients with Psoriasis and Cardiovascular Disease. Int J Mol Sci. 2021;22(19):1162.
   PubMed Web of Science ®Google Scholar
• Ataseven A, Temiz SA, Eren G, Ozer I, Dursun R. Comparison of anti-TNF and IL-inhibitors treatments in patients with psoriasis in terms of response to routine laboratory parameter dynamics. J Dermatolog Treat. 2022;33(2):1091–1096.
   PubMed Web of Science ®Google Scholar
• Vena GA, Vestita M, Cassano N. Can early treatment with biologicals modify the natural history of comorbidities? Dermatol Ther. 2010;23(2):181–193.
   PubMed Web of Science ®Google Scholar
• Kanelleas A, Liapi C, Katoulis A, et al. The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept. Clin Exp Dermatol. 2011;36(8):845–850.
   PubMed Web of Science ®Google Scholar
• Langley RG, Poulin Y, Srivastava B, et al. Reduced risk of mortality associated with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR): a nested case-control analysis. J Am Acad Dermatol. 2021;84(1):60–69.
   PubMed Web of Science ®Google Scholar